银屑病生物免疫治疗与炎症性关节炎发病时间的关联:一项回顾性队列研究
该回顾性队列研究基于美国TriNetX电子健康记录数据库,纳入2014年1月1日至2022年6月1日新接受生物制剂治疗的15501例成人银屑病患者,比较不同生物制剂与炎症性关节炎发病时间的关联。中位随访期间976例(6.3%)发生炎症性关节炎,累积发病率为2.6例/100人年;与TNF抑制剂相比,IL-12/23抑制剂(调整HR 0.58,95%CI 0.43-0.76)和IL-23抑制剂(调整HR 0.41,95%CI 0.17-0.95)与炎症性关节炎风险降低相关,IL-17抑制剂无显著差异。
要点
- 与TNF抑制剂相比,IL-12/23抑制剂(调整HR 0.58,95%CI 0.43-0.76)和IL-23抑制剂(调整HR 0.41,95%CI 0.17-0.95)与炎症性关节炎风险降低相关。
- IL-17抑制剂与TNF抑制剂相比无显著差异(调整HR 0.86,95%CI 0.54-1.38)。
- IL-12/23抑制剂的结果在所有敏感性分析中持续存在;IL-23抑制剂的结果在6项敏感性分析中的3项中持续存在。
核心结论
- 在这项大型银屑病患者队列研究中,与TNF抑制剂相比,IL-12/23抑制剂或IL-23抑制剂治疗与进展为炎症性关节炎的风险降低相关。
- 需要具备疾病活动度指标的前瞻性观察队列及对既往随机试验的汇总分析来证实这些发现。
研究设计与样本
- 本研究为回顾性队列研究,数据来自美国TriNetX网络的电子健康记录数据库中的全国患者样本。
- 纳入成人(年龄≥18岁)银屑病患者,要求相隔>30天有两个银屑病诊断代码(ICD代码),且新处方生物制剂(TNF、IL-17、IL-23或IL-12/23抑制剂,首次处方在获得首个银屑病诊断代码当日或之后)。
- 采用Kaplan-Meier估计绘制生物治疗开始后至首次出现银屑病关节炎或其他炎症性关节炎诊断代码的时间。
- 采用加权Cox比例风险回归计算炎症性关节炎的时间依赖性风险,以抗TNF暴露为参照,并调整人口学和临床协变量。
- 敏感性分析用于评估银屑病新发病例、延长炎症性关节炎患病病例的排除期、药物切换以及更严格的疾病和结局定义。
主要发现
- 2014年1月1日至2022年6月1日期间,共识别15501例银屑病患者(平均年龄50.2岁[SD 15.0];8399例[54.2%]女性,7102例[45.8%]男性;11175例[72.1%]白人)。
- 15501例患者中976例(6.3%)发生炎症性关节炎,累积发病率为2.6例/100人年。
- 多变量回归分析中,与处方TNF抑制剂的患者相比,处方IL-12/23抑制剂(调整HR 0.58,95%CI 0.43-0.76)或IL-23抑制剂(调整HR 0.41,95%CI 0.17-0.95)的患者发生炎症性关节炎的风险显著更低。
- 与TNF抑制剂相比,IL-17抑制剂未发现显著差异(调整HR 0.86,95%CI 0.54-1.38)。
- 对于IL-12/23抑制剂,结果在所有敏感性分析中持续存在;对于IL-23抑制剂,结果在6项敏感性分析中的3项中持续存在,即在使用更高的新发关节炎诊断阈值时以及排除首次生物制剂处方后3或6个月内发生关节炎的患者时。
关键数值与推荐
- 与TNF抑制剂相比,IL-12/23抑制剂的调整HR为0.58(95%CI 0.43-0.76)。
- 与TNF抑制剂相比,IL-23抑制剂的调整HR为0.41(95%CI 0.17-0.95)。
- 与TNF抑制剂相比,IL-17抑制剂的调整HR为0.86(95%CI 0.54-1.38)。
- 炎症性关节炎累积发病率为2.6例/100人年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要具备疾病活动度指标的前瞻性观察队列及对既往随机试验的汇总分析来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted biological immunotherapies have been highly effective in controlling skin disease in patients with psoriasis, but whether therapy delays progression to inflammatory arthritis is unclear. The aim of this study was to compare the time to incident inflammatory arthritis among patients newly receiving biological therapies for psoriasis. METHODS: In this retrospective cohort study, we obtained data on a national sample of patients in the USA from the electronic health records database of the US-based TriNetX network. We included adult patients (aged ≥18 years) with two diagnostic codes for psoriasis (>30 days apart; International Classification of Diseases [ICD] codes) who had been newly prescribed a biologic (inhibitors of tumour necrosis factor [TNF], interleukin [IL]-17, IL-23, or IL-12/23, first prescribed on or after the date of receiving a first psoriasis diagnosis code). The time to incident inflammatory arthritis, defined by first occurrence of a diagnostic code for psoriatic arthritis or other inflammatory arthritis after initiation of biological therapy, was graphed with use of the Kaplan-Meier estimate. Time-dependent risk for inflammatory arthritis was calculated with weighted Cox proportional hazards regression with anti-TNF exposure as the reference, adjusted for demographic and clinical covariables. Sensitivity analyses were used to evaluate incident cases of psoriasis, increased exclusion periods for prevalent cases of inflammatory arthritis, drug switching, and more stringent disease and outcome definitions. FINDINGS: Between Jan 1, 2014, and June 1, 2022, we identified 15 501 patients with psoriasis (mean age 50·2 years [SD 15·0]; 8399 [54·2%] women and 7102 [45·8%] men; 11 175 [72·1%] White). 976 (6·3%) of the 15 501 patients developed inflammatory arthritis, with a cumulative incidence of 2·6 cases per 100 person-years. In multivariable regression analyses, the risk of developing inflammatory arthritis was significantly lower in patients prescribed IL-12/23 inhibitors (adjusted HR 0·58, 95% CI 0·43-0·76) or IL-23 inhibitors (0·41, 0·17-0·95) than in patients prescribed TNF inhibitors. We found no significant difference for IL-17 inhibitors (0·86, 0·54-1·38) compared with TNF inhibitors. For IL-12/23 inhibitors, the results persisted in all sensitivity analyses. For IL-23 inhibitors, the results persisted in three of six sensitivity analyses, when a higher diagnostic threshold for incident arthritis was used and when excluding patients who developed arthritis within 3 or 6 months after first biologic prescription. INTERPRETATION: In this large cohort study of patients with psoriasis, treatment with IL-12/23 inhibitors or IL-23 inhibitors was associated with reduced risk of progression to inflammatory arthritis compared with TNF inhibitors. Prospective observational cohorts with disease activity measures and pooled analyses of previous randomised trials are required to confirm these findings. FUNDING: None.
引用
- Singla S, Putman M, Liew J, et al. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023. PMID: 38251522. doi:10.1016/S2665-9913(23)00034-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。